Novartis signs deal to boost cell therapy portfolio – Reuters
| Reuters The maker of blockbuster blood pressure drug Diovan said it would use a stem–cell based platform developed by U.S.-based biopharmaceutical company Regenerex to help broaden its cell therapy portfolio. Timothy Wright, head of development at Novartis … Novartis signs cell therapy deal with RegenerexPMLiVE Novartis announces an exclusive global licensing and research collaboration …ITNews |
